EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis

Joice Zuckermann, Bruno Mateus de Castro iD, Thiago Almirante Cunha, Alessandra Paz, Leila Beltrami Moreira iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0284476 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, 2023. Verfasst von Joice Zuckermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital de Clínicas de Porto Alegre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rabbit anti-thymocyte globulin (ATG) has been used in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) for graft-versus-host disease (GvHD) prophylaxis. Since the best dose has not been defined yet, this study aimed to determine the efficacy and safety of different doses of ATG in Allo-HSCT. Data sources were MEDLINE/PUBMED, EMBASE, Cochrane Library, Web of Science, LILACS, and SciELO. Studies were eligible when comparing doses of ATG. The higher dose was in the intervention group. A total of 22 articles (2002–2022) were included. Higher doses (4–12 mg/kg) of ATG-T reduced the incidence of grade III-IV acute GvHD (RR 0.60; 95%CI 0.42–0.84) and limited chronic GvHD (RR 0.64 95%CI 0.45–0.92) compared with lower doses (2–7.5 mg/kg). Higher doses increased the Epstein-Barr virus (RR 1.90 95% CI 1.49–2.42) and Cytomegalovirus reactivation (RR, 1.30; 95% CI 1.03–1.64). Relapse rates were higher in the higher dose group (RR 1.34, 95% CI 1.07–167). The ATG-T dose ≥7mg/kg versus the lower dose showed a number needed to treat 7.4 for acute GvHD III-IV, with a number to harm of 7.7 for relapse at one year in the higher dose group. A dose lower than 7 mg/kg suggests a better risk-benefit ratio than a higher one. Well-designed RCT is needed to define the best risk-benefit doses. Trial registration: Trial registration number: PROSPERO: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020173449 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansAntilymphocyte SerumTransplantation, HomologousHerpesvirus 4, HumanRecurrenceChronic DiseaseRetrospective Studies

Substanzen

Antilymphocyte Serum

Autor:innen und Institutionen

  • Graduate Program in Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • Nursing School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

ORCID-Profile: Bruno Mateus de Castro, Leila Beltrami Moreira

Förderung

  • Hospital de Clínicas de Porto Alegre

Zitieren

APA

Zuckermann, J., Castro, B. M., Cunha, T. A., Paz, A., & Moreira, L. B. (2023). Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLOS ONE. https://doi.org/10.1371/journal.pone.0284476

Vancouver

Zuckermann J, Castro BM, Cunha TA, Paz A, Moreira LB. Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLOS ONE. 2023. doi:10.1371/journal.pone.0284476

BibTeX
@article{Zuckermann2023,
  author = {Zuckermann, Joice and Castro, Bruno Mateus de and Cunha, Thiago Almirante and Paz, Alessandra and Moreira, Leila Beltrami},
  title = {Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0284476}
}
Kostenlos starten →